Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
6/26/2026, 12:00:00 AM
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
Korean Translation
2026년 6월 26일 연례 주주총회에서 2025년 실적 및 배당 승인 예정. 분석가들은 통상적인 행사에 따른 1-5%의 주가 영향이 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.
6/4/2026, 12:00:00 AM